TY - JOUR T1 - Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada JF - medRxiv DO - 10.1101/2020.12.04.20244194 SP - 2020.12.04.20244194 AU - Thomas N. Vilches AU - Shokoofeh Nourbakhsh AU - Kevin Zhang AU - Lyndon Juden-Kelly AU - Lauren E. Cipriano AU - Joanne M. Langley AU - Pratha Sah AU - Alison P. Galvani AU - Seyed M. Moghadas Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/31/2020.12.04.20244194.abstract N2 - The novel coronavirus disease 2019 (COVID-19) has caused severe outbreaks in Canadian long-term care facilities (LTCFs). In Canada, over 80% of COVID-19 deaths during the first pandemic wave occurred in LTCFs. We sought to evaluate the effect of mitigation measures in LTCFs including frequent testing of staff, and vaccination of staff and residents. We developed an agent-based transmission model and parameterized it with disease-specific estimates, temporal sensitivity of nasopharyngeal and saliva testing, results of vaccine efficacy trials, and data from initial COVID-19 outbreaks in LTCFs in Ontario, Canada. Characteristics of staff and residents, including contact patterns, were integrated into the model with age-dependent risk of hospitalization and death. Estimates of infection and outcomes were obtained and 95% credible intervals were generated using a bias-corrected and accelerated bootstrap method. Weekly routine testing of staff with 2-day turnaround time reduced infections among residents by at least 25.9% (95% CrI: 23.3% - 28.3%), compared to baseline measures of mask-wearing, symptom screening, and staff cohorting alone. A similar reduction of hospitalizations and deaths was achieved in residents. Vaccination averted 2-4 times more infections in both staff and residents as compared to routine testing, and markedly reduced hospitalizations and deaths among residents by 95.9% (95% CrI: 95.4% - 96.3%) and 95.8% (95% CrI: 95.5% - 96.1%), respectively, over 200 days from the start of vaccination. Vaccination could have a substantial impact on mitigating disease burden among residents, but may not eliminate the need for other measures before population-level control of COVID-19 is achieved.Competing Interest StatementDr. Joanne M. Langley reports that her institution has received funding for research studies from Sanofi Pasteur, GlaxoSmithKline, Merck, Janssen and Pfizer. Dr. Joanne M. Langley also holds the CIHR-GSK Chair in Pediatric Vaccinology at Dalhousie University. Other authors declare no competing interests.Funding StatementSMM was supported by the Canadian Institutes of Health Research (OV4 - 170643); Natural Sciences and Engineering Research Council of Canada; and the Canadian Foundation for Innovation. APG was supported by the National Science Foundation (RAPID - 2027755), and the National Institutes of Health (1RO1AI151176-01). TNV was supported by the São Paulo Research Foundation (FAPESP grant 2018/24811-1). LEC was supported by the Society for Medical Decision Making COVID-19 Decision Modeling Initiative funded by the Gordon and Betty Moore Foundation through Grant GBMF9634 to Johns Hopkins University and a Western University Catalyst Research Grant. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the York University Ethics Review Board (Project: 2020-269). The study was categorized as minimal risk, with no requirement for individual consent or participation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe computational model was implemented in Julia language and is available at: https://github.com/thomasvilches/LTCF-covid. https://github.com/thomasvilches/LTCF-covid ER -